Skip to content
2000
image of Response to the Letter to the Editor: Rare Endocrine Disorders and Peripheral Arterial Disease

There is no abstract available.

Loading

Article metrics loading...

/content/journals/cvp/10.2174/0115701611372375241125111238
2024-12-04
2025-01-18
Loading full text...

Full text loading...

References

  1. Poredoš P. Schernthaner G.H. Blinc A. Mikhailidis D.P. Antignani P.L. Anagnostis P.G. Jensterle M. Studen K.B. Šabović M. Jezovnik M.K. Endocrine disorders and peripheral arterial disease: A series of reviews. Curr. Vasc. Pharmacol. 2023 21 3 147 148 10.2174/1570161121666230516141319 37194233
    [Google Scholar]
  2. Blinc A. Schernthaner G.H. Poredoš P. Anagnostis P. Jensterle M. Studen K.B. Antignani P.L. Mikhailidis D.P. Šabović M. Testosterone and peripheral arterial disease. Curr. Vasc. Pharmacol. 2023 21 5 297 303 10.2174/1570161121666230809143023 37559242
    [Google Scholar]
  3. Anagnostis P. Mikhailidis D.P. Blinc A. Jensterle M. Ježovnik M.K. Schernthaner G.H. Antignani P.L. Studen K.B. Šabović M. Poredos P. The effect of menopause and menopausal hormone therapy on the risk of peripheral artery disease. Curr. Vasc. Pharmacol. 2023 21 5 293 296 10.2174/0115701611263345230919122907 37779405
    [Google Scholar]
  4. Janez A. Herman R. Poredos P. Mikhailidis D.P. Blinc A. Sabovic M. Studen K.B. Jezovnik M.K. Schernthaner G.H. Anagnostis P. Antignani P.L. Jensterle M. Cardiometabolic risk, peripheral arterial disease and cardiovascular events in polycystic ovary syndrome: Time to implement systematic screening and update the management. Curr. Vasc. Pharmacol. 2023 21 6 424 432 10.2174/0115701611269146230920073301 37779406
    [Google Scholar]
  5. Studen K.B. Gaberscek S. Zaletel K. Blinc A. Sabovic M. Schernthaner G.H. Anagnostis P. Antignani P.L. Jensterle M. Mikhailidis D.P. Poredos P. Thyroid disorders and peripheral arterial disease. Curr. Vasc. Pharmacol. 2024 22 1 36 40 10.2174/0115701611271284231105063148 37957913
    [Google Scholar]
  6. R H. A J. Dp M. P P. A B. M S. K B.S. Gh S. P A. Pl A. M J. Growth hormone, atherosclerosis and peripheral arterial disease: Exploring the spectrum from acromegaly to growth hormone deficiency. Curr. Vasc. Pharmacol. 2024 22 1 28 35 10.2174/0115701611269162231106042956 37962050
    [Google Scholar]
  7. P P. Gh S. A B. Dp M. M J. P A. Pl A. K B.S. M Š. Mk J. Endocrine disorders and peripheral arterial disease – A series of reviews Cushing syndrome-cortisol excess. Curr. Vasc. Pharmacol. 2024 22 4 236 241 10.2174/0115701611272145231106053914 38038006
    [Google Scholar]
  8. Antignani P.L. Jezovnik M.K. Blinc A. Mikhailidis D.P. Anagnostis P. Schernthaner G.H. Jensterle M. Studen K.B. Sabovic M. Poredos P. Hyperparathyroidism and peripheral arterial disease. Curr. Vasc. Pharmacol. 2024 22 2 88 94 10.2174/0115701611280905231227045826 38284694
    [Google Scholar]
  9. Papaioannou V. Tsiantoula P. Rare endocrine disorders and peripheral arterial disease. Curr Vasc Pharmacol 2024
    [Google Scholar]
  10. Ngaosuwan K. Johnston D. Godsland I. Cardiovascular disease in patients with primary and secondary adrenal insufficiency and the role of comorbidities. J Clin Endocrinol Metab 2021 106 5 1284 1293 10.1210/clinem/dgab063
    [Google Scholar]
  11. Zhao R. Luo S. Wang S. Wen Y. Xiong F. Coronary artery disease in a patient with Addison’s disease: A case report and literature review. BMC Cardiovasc. Disord. 2023 23 1 54 10.1186/s12872‑023‑03079‑0 36709280
    [Google Scholar]
  12. Guarnotta V. Di Stefano C. Tomasello L. Maniscalco L. Pizzolanti G. Arnaldi G. Giordano C. Conventional steroids vs. dual-release hydrocortisone on metabolic, cardiovascular, and bone outcomes in adrenal insufficiency: A 10-year study. Eur. J. Endocrinol. 2024 191 3 300 311 10.1093/ejendo/lvae107 39171906
    [Google Scholar]
  13. Ntali G. Markussis V. Chrisoulidou A. An overview of cardiovascular risk in pituitary disorders. Medicina 2024 60 8 1241 10.3390/medicina60081241 39202522
    [Google Scholar]
  14. Mastnak L. Herman R. Ferjan S. Janež A. Jensterle M. Prolactin in polycystic ovary syndrome: Metabolic effects and therapeutic prospects. Life 2023 13 11 2124 10.3390/life13112124 38004264
    [Google Scholar]
  15. Feldman R.D. Sanjanwala R. Padwal R. Leung A.A. Revising the roles of aldosterone in vascular physiology and pathophysiology: From electocortin to baxdrostat. Can. J. Cardiol. 2023 39 12 1808 1815 10.1016/j.cjca.2023.08.035 37734710
    [Google Scholar]
  16. Petramala L. Concistrè A. Mezzadri M. Sarlo F. Circosta F. Schina M. Soldini M. Iannucci G. Letizia C. Relationship between plasma aldosterone levels and arterial stiffness parameters in hypertensive patients with subclinical vascular damage. Int. J. Cardiol. Cardiovasc. Risk Prev. 2022 14 200138 10.1016/j.ijcrp.2022.200138 36060288
    [Google Scholar]
/content/journals/cvp/10.2174/0115701611372375241125111238
Loading

  • Article Type:
    Editorial
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test